Gilead oral IBS drug eliminates symptoms in mid-stage trial

Gilead Sciences reported mid-stage trial results showing its oral treatment eliminated symptoms in patients with a type of inflammatory bowel disease. The data is preliminary and not yet peer-reviewed, but suggests a potential new therapeutic option. This is a company-specific clinical development with no immediate macro-market implications.